Etanercept is suggested above other TNF-α inhibitors to minimize the risk of tuberculosis infection in individuals with latent tuberculosis infection reactivation or previously treated tuberculosis (Godfrey and Friedman, 2019). Here, TNF is linked to tuberculosis.